New combo aims to keep myeloma in check after CAR t
NCT ID NCT06048250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new pill, mezigdomide, given after CAR T-cell therapy (Abecma) in 15 adults with multiple myeloma that has returned. The goal is to see if the drug is safe and can help the CAR T cells last longer to better control the cancer. Participants must have tried at least four prior treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact